6 results about "ErbB" patented technology

To provide: compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK; pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof; and pharmaceutical compositions comprising the compounds.SOLUTION: The invention provides compounds represented by the formula (I), pharmaceutically acceptable salts, esters, hydrates, solvates or stereoisomers thereof.SELECTED DRAWING: None

The application discloses a monoclonal antibody against mouse receptor tyrosine protein kinase Erbb-3 and application thereof. The monoclonal antibody comprises an R138 monoclonal antibody, wherein the light chain CDR1-3 of the R138 antibody are respectively shown as SEQ ID NO. 23-SEQ ID NO. 25, and the heavy chain CDR1-3 are respectively shown as SEQ ID NO. 26-SEQ ID NO. 28. The application further provides a kit comprising the above antibody, which has the advantages of good detection stability, high accuracy, high sensitivity and good specificity, and is suitable for quantitative detection of mouse receptor tyrosine protein kinase Erbb-3 protein.

Provided herein are ex vivo methods of engineering or culturing a submucosal gland (SMG) organoid, comprising isolating submucosal gland basal cells and / or myoepithelial cells (e.g., human cells), and / or submucosal gland stem and / or progenitor cells (e.g., human cells), and culturing such cells with an agonist or ligand of ERBB (e.g., in a three- dimensional matrix). Also provided herein are SMG organoid engineered or cultured ex vivo. Also provided herein are methods of identifying an agent that reduces airway mucus production using an ex vivo SMG organoid described herein. Also provided herein is a method of treating a hypersecretory airway disorder or disease, or a disorder associated with an increased secretion from submucosal glands, in a subject, comprising administering to the subject an agent that inhibits ERBB.

The present invention relates to the use of nucleotide synthesis pathway inhibitors and macropinocytosis inhibitors for the treatment of tumors. The present disclosure provides the use of nucleotide synthetic pathway inhibitors and macropinocytosis inhibitors in the preparation of medicaments or kits for the treatment of tumors, where the nucleotide synthetic pathway inhibitors may include pyrimidine and / or purine synthetic pathway inhibitors such as orotic dehydrogenase (DHODH) inhibitors and phosphoribose pyrophosphate synthetase 1 (PRPS) inhibitors, the macropinocytosis inhibitor can comprise a macropinocytosis substrate uptake inhibitor, a PAK1 inhibitor, an EGFR signal pathway inhibitor, an ErbB signal pathway inhibitor, an NF-KB signal pathway inhibitor, an EREG inhibitor, a p65 inhibitor and an AREG inhibitor. The invention discloses a new way for activating macropinocytosis by using intracellular signals, provides a new insight for a regulation mechanism in tumor cells, and provides a new method for tumor treatment.

Genetically modified non-human animals that express a human or chimeric (e.g., humanized)ERBB, and methods of use thereof are disclosed.

The application belongs to the field of biological medicine, and relates to application of chondroitin acid protein 1 in preparation of a reagent for diagnosing lung adenocarcinoma or evaluating lung adenocarcinoma prognosis. The application screens CRTAC1 from a GEO database through bioinformatics analysis and a machine learning algorithm, and the CRTAC1 is significantly lowly expressed in lung adenocarcinoma tissues, and an AUC reaches 0.972. Verification of a GEPIA database shows that low expression of the CRTAC1 is significantly related to poor prognosis such as advanced pathological stages, and a patient with high expression has better prognosis. The CRTAC1 blocks epithelial-mesenchymal transition through inhibition of an EGF / ErbB signal path, and remodels a tumor immune microenvironment through inhibition of M2 type macrophage polarization. A mouse lung metastasis model proves that overexpression of the CRTAC1 significantly reduces lung metastasis nodules. The application provides a new molecular marker and a drug target for early diagnosis, prognosis evaluation and precise treatment of lung adenocarcinoma.